Literature DB >> 25050898

Resistance training does not protect against increases in plasma cytokine levels among germ cell cancer patients during and after chemotherapy.

Jesper F Christensen1, Anders Tolver, Jesper L Andersen, Mikael Rørth, Gedske Daugaard, Pernille Hojman.   

Abstract

CONTEXT: Testicular germ cell cancer (GCC) patients treated with cisplatin-etoposide-bleomycin chemotherapy (BEP) have excellent prognosis but have an increased risk of late-occurring morbidities, which may be associated with changes in the inflammatory profile.
OBJECTIVE: The objective of the study was to explore plasma cytokine concentrations in GCC patients randomized to resistance training or usual care during BEP, in comparison with healthy controls. DESIGN/
SETTING: This was a randomized controlled trial in GCC patients enrolled from an oncology clinic, including a healthy reference group for comparison purposes. OUTCOME MEASURES: Plasma granulocyte macrophage colony-stimulating factor, interferon-γ, IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12, and TNF-α were measured in fasting blood samples from GCC patients randomized to resistance training (INT; n = 15) or usual care (CON; n = 15) and healthy age-matched controls (REF; n = 19). Clinical toxicity assessments and patient-reported end points were also recorded.
RESULTS: CON and INT were balanced at baseline. Compared with REF, CON had higher concentrations of IL-10, IL-6, and interferon-γ, and INT had higher concentrations of IL-6, IL-8 and TNF-α (all P < .05). At the end of therapy, concentrations of IL-6, IL-8, and IL-10 increased in both GCC groups (all P < .01). Three months after therapy, all cytokine concentrations were comparable with the pretreatment levels in both GCC-groups but remained elevated compared with REF (P < .05). Changes in TNF-α correlated with pulmonary toxicity (P < .01). At the end of therapy, IL-6 concentrations correlated with quality of life (P < .05) and fatigue (P < .01).
CONCLUSION: GCC patients treated with BEP display consistently elevated levels of systemic inflammatory markers compared with healthy controls. Resistance training during therapy has no impact on plasma cytokine concentrations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25050898     DOI: 10.1210/jc.2013-4495

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Exploratory Investigation of Early Biomarkers for Chronic Fatigue in Prostate Cancer Patients Following Radiation Therapy.

Authors:  Li Rebekah Feng; Brian S Wolff; Nada Lukkahatai; Alexandra Espina; Leorey N Saligan
Journal:  Cancer Nurs       Date:  2017 May/Jun       Impact factor: 2.592

Review 2.  Treatment-related cardiovascular late effects and exercise training countermeasures in testicular germ cell cancer survivorship.

Authors:  Jesper F Christensen; Mikkel Bandak; Anna Campbell; Lee W Jones; Pernille Højman
Journal:  Acta Oncol       Date:  2015-03-09       Impact factor: 4.089

3.  Effects of a multimodal rehabilitation programme on inflammation and oxidative stress in oesophageal cancer survivors: the ReStOre feasibility study.

Authors:  Emer M Guinan; Suzanne L Doyle; Linda O'Neill; Margaret R Dunne; Emma K Foley; Jacintha O'Sullivan; John V Reynolds; Juliette Hussey
Journal:  Support Care Cancer       Date:  2016-11-03       Impact factor: 3.603

4.  Effects of exercise on inflammation in patients receiving chemotherapy: a nationwide NCORP randomized clinical trial.

Authors:  Ian R Kleckner; Charles Kamen; Calvin Cole; Chunkit Fung; Charles E Heckler; Joseph J Guido; Eva Culakova; Adedayo A Onitilo; Alison Conlin; J Philip Kuebler; Supriya Mohile; Michelle Janelsins; Karen M Mustian
Journal:  Support Care Cancer       Date:  2019-04-02       Impact factor: 3.603

Review 5.  Effectiveness of Resistance Training on Fatigue in Patients Undergoing Cancer Treatment: A Meta-Analysis of Randomized Clinical Trials.

Authors:  Lily Berríos Contreras; Rodrigo Cuevas Cid; Luz Alejandra Lorca; Ivana Leão Ribeiro
Journal:  Int J Breast Cancer       Date:  2022-08-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.